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Introduction
Examination of the retinal blood ves-
sels provides a direct view of the
human microvasculature and allows
the study of autoregulatory responses
that are mediated via difference mech-
anisms (e.g. metabolic and myogenic)
(Patton et al. 2006). Retinal structure
and function is altered in individuals
with diabetes (Pournaras et al. 2008)
and is proposed to contribute to the
pathogenesis of diabetic retinopathy
(Kohner et al. 1995; Grunwald et al.
1996; Schmetterer & Wolzt 1999).
Thus, the study of retinal vascular
function can provide important infor-
mation about predisposition to vascu-
lar diseases associated with diabetes
(Patton et al. 2006; Pournaras et al.
2008).
Vascular reactivity, which is the
change in magnitude of a haemody-
namic variable in response to a
provocative stimulus, is a measure of
vascular function. Flickering light and
hyperoxia are two well-known provoc-
ative metabolic stimuli for the retinal
vasculature (Pournaras et al. 2008).
Flickering light stimulation involves a
short series of light ﬂashes for a speci-
ﬁed time period (e.g. 15–64 seconds),
which causes retinal blood vessels to
vasodilate resulting in increased
retinal blood ﬂow and blood vessel
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ABSTRACT.
Purpose: The retinal blood vessels provide a unique way to directly examine the human
microvasculature, which is frequently damaged in individuals with diabetes. Previous
studies have demonstrated that retinal ﬂickering light-induced vasodilation and hyperox-
ia-induced vasoconstriction may operate by enhancing or reducing similar vasoregulatory
factor(s), but a comparison between these two provocative stimuli in individuals with
diabetes has not been studied. The purpose of the study was to examine the association
between retinal ﬂickering light-induced vasodilation and retinal hyperoxia-induced vaso-
constriction in type 2 diabetic subjects and in healthy controls.
Methods: Twenty men and women with type 2 diabetes and 10 men and women without
diabetes between 21 and 75 years of age were recruited. Changes in retinal artery and vein
diameters to ﬂickering light and during hyperoxia (100% oxygen) stimuli were measured
on the same visit using a noninvasive retinal imaging device (Dynamic Vessel Analyzer,
Imedos Inc., Germany).
Results: Compared with controls, diabetic subjects had impaired arterial vasodilator
and vasoconstrictor responses to both ﬂickering light and hyperoxia, respectively (both
p < 0.001). Merging both groups, an inverse correlation (r = )0.56; p = 0.003)
between the retinal artery’s responses to ﬂickering light-induced vasodilation and hyper-
oxia-induced vasoconstriction was demonstrated independent of glucose or insulin levels.
Conclusion: This suggests that both responses are attenuated to a similar degree in dia-
betic subjects and that the attenuation to both stimuli can be observed in retinal arteries
and veins. This would suggest that similar vasoregulatory factor(s) might in part help
to explain the retinal diameter responses between the two stimuli. One suggested com-
mon vasoregulator of vascular tone is nitric oxide; however, other factor(s) may be
involved, which contribute to this association and require further research.
Key words: diabetes – ﬂickering-induced vasodilation – hyperoxia – retinal reactivity – vasocon-
striction – vasodilation
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diameter in healthy individuals (For-
maz et al. 1997; Michelson et al. 2002;
Dorner et al. 2003; Nagel et al. 2004).
By contrast, retinal blood vessel diam-
eter constricts and blood ﬂow
decreases in response to hyperoxia in
healthy individuals (Riva et al. 1983;
Kiss et al. 2002; Gilmore et al. 2005;
Jean-Louis et al. 2005). Both vasodila-
tor responses (Grunwald et al. 1984;
Garhofer et al. 2004; Mandecka et al.
2007; Pemp et al. 2009) and vasocon-
strictor responses are attenuated in
diabetes (Gilmore et al. 2007; Justesen
et al. 2010). However, whether a rela-
tionship exists between these two stim-
uli is unclear, as the majority of
retinal studies have reported retinal
vasoreactivity to either one or the
other of these stimuli without direct
comparison in vasoreactivity to both
stimuli. An early study conducted in
only three healthy subjects suggested
that the vasoconstrictor response to
hyperoxia compared with magnitude
of the ﬂickering light-induced vasodi-
lation was greater (Formaz et al.
1997); This study had technical limita-
tions in the set-up used for the admin-
istration of oxygen, which may have
lead to changes in carbon dioxide lev-
els, and used static instead of dynamic
fundus photographs, which did not
allow continuous measurements of
changes in retinal vessel diameters.
Few studies have examined the
potential underlying mechanisms that
lead to retinal vasodilation and vaso-
constriction by ﬂickering light and hy-
peroxia. Animal and human retinal
studies suggest that part of the ﬂicker-
ing light-induced vasodilation can be
explained by an increase in nitric
oxide (Buerk et al. 1996; Kondo et al.
1997; Dorner et al. 2003). Peripheral
and coronary blood ﬂow studies in
animals and humans suggest that part
of the blood vessel vasoconstriction
associated with hyperoxia can be
explained through the increase of
reactive oxygen species, which can
reduce or quench nitric oxide
availability (Rubanyi & Vanhoutte
1986; Mak et al. 2002; McNulty et al.
2007). Therefore, both hyperoxia and
ﬂicker may evoke vasoconstriction
and dilation in part via modulation
(i.e. reduction or enhancement) of a
similar vasoregulator factor (i.e. nitric
oxide).
Thus, the purpose of the study was
to examine the association between
ﬂickering light-induced vasodilation
and hyperoxia-induced vasoconstric-
tion in healthy and type 2 diabetic
individuals. As both stimuli may mod-
ulate the vasoregulator factor, nitric
oxide, we hypothesized that ﬂickering
light-induced vasodilation and hyper-
oxia-induced vasoconstriction may
have similar magnitude changes and
be inversely correlated in these popu-
lations. This information could be
helpful in understanding the range of
responsiveness in the human retinal
vessels to common regulatory systems
in health and disease.
Methods
Subjects
The study was approved by Penn
State Hershey Medical Center’s Insti-
tutional Review Board and followed
the Tenets of the Declaration of Hel-
sinki. Twenty men and women with
type 2 diabetes and 10 men and
women without diabetes between 21
and 75 years of age were enrolled into
the study. Diabetic subjects were indi-
viduals diagnosed with diabetes by
their physician. After signing informed
consent, all subjects completed a med-
ical history, physical exam and ocular
screening, which included a measure-
ment of visual acuity. Subjects had a
normal eye examination with cor-
rected acuity 20 ⁄30 or better and
intraocular pressures below 21 mmHg.
Subjects were free from stroke, heart,
lung and eye diseases (e.g. retinopa-
thy, age-related macular degeneration
or glaucoma) and from morbid
obesity (body mass index (BMI) >
40 kg ⁄m2) and were not pregnant. All
subjects were nonsmokers, and con-
trols had no history of hypertension.
Experimental design
The retinal diameter responses to ﬂick-
ering light and hyperoxia were mea-
sured during one visit with a 15-min rest
period between experimental trials
(Fig. 1). The Dynamic Vessel Analyzer
(DVA) measured retinal reactivity.
Subjects refrained from alcohol, caf-
feine and exercise for 24 hr prior to test-
ing. Measurements were performed in a
dimly lit room with temperature 68–70
with subjects in a fasted state for
approximately 10 hr. Individuals with
type 2 diabetes refrained from using all
medications in the morning of the
study. Aspirin and nonsteroidal anti-
inﬂammatory medications were held for
72 hr prior to the study. After a 15-min
rest period, venous blood samples from
the antecubital location were drawn for
later analysis. The eye with the best
visual acuity was dilated with one drop
of tropicamide (1%). If needed, phenyl-
ephrine (2.5%) was additionally used to
obtain optimal dilation.
Experimental protocol
An initial room air breathing period
was used to allow stabilization of
baseline parameters. Hyperoxia was
induced by administrating 100% oxy-
gen via a rubber mouthpiece, which
was snugly ﬁtted into the subject’s
mouth. Nares were clipped closed to
ensure that the subject was breathing
only through the mouth. The mouth-
piece was connected to a six-inch
tube which was then connected to a
T-piece which had a one-way valve on
either side for inhalation and exhala-
tion. Oxygen was delivered through a
reservoir bag, which connected to
the one-way inhalation valve T-piece.
While sitting, the subject’s retinal
Fig. 1. Diagram of the experimental protocol. After a 15-min rest period, retinal vascular diam-
eters were measured at room air for 1 min followed by 100% oxygen for 5 min. Retinal images
were recorded during the 3-min recovery period back at room air. After a minimum rest period
of 15 min, retinal baseline diameters for the ﬂicker trial were collected followed by three series
of ﬂicker (20 seconds) and recovery periods (80 seconds) for a total of 6 min.
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vessel diameters were imaged continu-
ously during each stimulus using the
DVA. Following 1 min of baseline
with inhalation of room air, 100%
oxygen was administered for 5 min
followed by a 3-min recovery period
back at room air. After a minimal
rest period of 15 min, ﬂickering light
measurements were conducted as the
subject’s retinal vessels were imaged
continuously. After 50 seconds of
baseline, the ﬂickering light stimulus
involved three cycles of light ﬂashes
(20 seconds) at a 12.5 Hz frequency
followed by 80 seconds of a rest per-
iod between each series of light ﬂashes
(Mandecka et al. 2007; Nguyen et al.
2009). The entire measurement lasted
6 min. Blood pressure (BP) and heart
rate (HR) were measured continu-
ously during the studies. Additionally,
end tidal CO2 (ETCO2) and ﬁnger
oxygen saturation (O2Sat) were contin-
uously measured during the hyperoxia
trial (See Fig. 1 for experimental pro-
tocol paradigm).
Measurements
Retinal vessel diameters
The DVA (Imedos Inc., Germany) uses
a modiﬁed fundus camera (Zeiss
FF450; Zeiss Jena, Germany) and a
video recording unit. The system scans
retinal diameters in real time, and ves-
sel calibres can be analysed off-line
(Garhofer et al. 2010). To obtain
images, the subjects’ ﬁxation in the fun-
dus camera was adjusted so that the
optic nerve head was in the centre of
the fundus monitor. The fundus cam-
era focus and green background light
were adjusted to provide sharp images
on the fundus monitor. The region of
interest was marked over a superior or
inferior temporal retinal artery and
vein one to two optic disc diameters
from the optic nerve disc. This region
of interest is measured 25 times per sec-
ond, and measurements are reported in
arbitrary units (AU). Eye-tracking
technology in the DVA compensates
for small eye movements. Throughout
the testing, the subject was verbally
urged to maintain his ⁄her ﬁxation on
the ﬁxation pointer within the DVA
and to blink frequently to maintain
crisp images. All images were stored on
a VHS videotape recorder for off-line
measurements of retinal artery and
vein diameters. One observer analysed
all measurements.
Haemodynamics (HR and BP)
Heart rate derived from the electro-
cardiogram and BP measured by use
of a Finometer device (model 2300;
Ohmeda, Boulder, CO, USA, con-
ﬁrmed by an automated sphygmoma-
nometer, Dinamap, Critikon, Tampa,
FL, USA) were measured continu-
ously and collected on-line at 200 Hz.
Ventilatory parameters
ET CO2 (%) was measured continu-
ously with a respiratory gas monitor
during the hyperoxia trials (RGM
5250; Ohmeda, Madison, WI, USA).
O2Sat (%) was measured using a ﬁnger
pulse oximeter (Model Biox 3740; Oh-
meda, Louisville, CO, USA).
Plasma biomarkers
Fasting glucose, insulin, haemoglobin
(HB)A1C and lipid proﬁle were mea-
sured using radioimmunoassays
(Diagnostic Products Corp., Los
Angeles, CA, USA).
Statistical analysis
For ﬂickering light experimental trials,
the resting baseline measurements
were averaged from the last 15 sec-
onds of resting conditions, and peak
retinal dilation was captured from
the last 3–10 seconds of the ﬂickering
stimuli and the ﬁrst 3 seconds after
the stimulus ended (Mandecka et al.
2007). The percentage change in vessel
diameter was calculated comparing
baseline retinal diameter with the dia-
meter at a speciﬁc time point using
the following equation: Per cent
change in diameter = (((diameterx )
diameterbaseline) ⁄diameterbaseline) · 100).
We also measured maximal retinal
vasoconstriction after peak diameter
dilation (i.e. smallest diameter after
peak dilation – averaged of 4 sec-
onds). Lastly, we calculated the over-
all range of change in the retinal
diameter known as relative amplitude
(percent change in relative ampli-
tude = percent change in peak dila-
tion + Œpercent change in maximal
vasoconstriction) (Nagel et al. 2004).
For the hyperoxia trials, the last
30 seconds of resting baseline and last
15 seconds of 5 min of hyperoxia were
measured and the percent change
from baseline was calculated.
Two-tailed unpaired t-tests were
used to compare demographic, anth-
ropometric, blood samples and resting
haemodynamic variables between the
two groups (healthy controls and type
2 diabetic subjects). Analysis of vari-
ance models were ﬁt to continuous
outcomes to assess differences between
the independent factors of group (con-
trols and diabetic subjects) and retinal
vessel (artery and vein), as well as the
interaction of group and retinal vessel.
With the groups’ data merged, the
correlations between two continuous
variables (vascular reactivity responses
to hyperoxia and ﬂickering light stim-
uli) were assessed using Pearson’s cor-
relation coefﬁcients and partial
correlations adjusted for covariates
(glucose and insulin). Results are pre-
sented as means ± SD. A p < 0.05
was regarded as signiﬁcant.
Results
Subject characteristics
Groups were comparable in age,
weight and BMI (Table 1). Most of
the diabetic subjects were treated with
oral diabetic medications (87%) and
several with combination therapy with
long- and ⁄or short-acting insulin
(20%). The majority of those with
diabetes were also on anti-hyperten-
sion (93%) and statin (60%) therapy.
Diabetic subjects had higher fasting
glucose and HbA1C levels compared
with healthy controls (Table 1). Com-
pared with control subjects, diabetic
subjects tended to have a greater rest-
ing HR, but no differences in resting
mean arterial pressure (MAP), systolic
blood pressure (SBP) or diastolic
blood pressure (DBP) were noted
(Table 2). Resting retinal artery and
vein diameters within groups were
similar at baseline prior to the two
stimuli (Controls: artery, 116 ± 11
AU and 116 ± 6 AU; vein, 133 ± 18
AU and 136 ± 20 AU, prehyperoxia
and preﬂicker, respectively; Diabetic
subjects: artery, 118 ± 17 AU and
118 ± 15 AU; Vein, 147 ± 22 and
AU 148 ± 24 AU, prehyperoxia and
preﬂicker, respectively, all p > 0.05).
Hyperoxia-induced vasoconstriction
Finger pulse O2Sat from baseline levels
increased in both groups during hy-
peroxia (Controls: 98 ± 1% to 100 ±
1%, p = 0.003; Diabetic subjects:
98 ± 0% to 99 ± 0%, p < 0.001).
Hyperoxia evoked similar artery and
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vein vasoconstriction in the majority
(90%) of healthy controls, whereas
artery and vein diameters decreased
in only 50% of the diabetic subjects
in response to oxygen. Compared
with healthy subjects, diabetic subjects
had signiﬁcantly attenuated artery and
vein constrictor responses to hyperoxia
(Fig. 2, Group effect, p = 0.000).
Hyperoxia did not signiﬁcantly
change HR, MAP, SBP or DBP in
either group (data not shown).
ETCO2 did not signiﬁcantly change
after 5 min of hyperoxia from baseline
levels in either group (controls:
5.3 ± 0.5% to 5.4 ± 0.5%, p =
0.10; diabetic subjects: 4.9 ± 0.8% to
4.7 ± 1.1%; p = 0.34).
Flickering Light-Induced vasodilation
Flickering light evoked vasodilation in
the majority in each group (95% in
controls and 91% in diabetic sub-
jects), although the artery and vein
peak vasodilator responses were sig-
niﬁcantly attenuated in the diabetic
group compared with the healthy con-
trol group (Fig. 3A, group effect,
p < 0.001). Retinal vein diameters
increased to a greater extent at peak
vasodilation compared with retinal
artery diameters (vessel effect,
p = 0.022).
Maximal vasoconstriction after
peak vasodilation was similar in the
two groups and between vessels
(Fig. 3B). Compared with healthy
controls, diabetic subjects had attenu-
ations in their overall per cent change
in relative amplitude for the artery
and vein responses to ﬂickering light
(Fig. 3C, p < 0.001). Flickering light
stimuli did not signiﬁcantly change
resting HR, MAP, SBP or DBP in
either group (Data not shown).
Hyperoxia compared with ﬂickering light
reactivity responses
The healthy control group had similar
changes in magnitude (% change) in
the retinal artery and vein between the
two different stimuli (artery, p =
0.87; and vein, p = 0.57). Diabetics
had a greater magnitude change to
peak ﬂicker than hyperoxia in the
artery (p = 0.03) but not the vein
(p = 0.17), whereas their artery and
vein responses to hyperoxia were
smaller in magnitude to their relative
amplitude responses to ﬂicker in both
vessels (p < 0.001 and p = 0.005,
respectively). When controls and dia-
betic groups were combined, we
observed a signiﬁcant inverse relation-
ship in the retinal arteries between the
magnitude of the constrictor responses
to hyperoxia and peak dilator
responses to ﬂickering light (r = )0.56,
p = 0.003; Fig. 4A). We observed a
similar relationship between magni-
tude of the constrictor responses to
hyperoxia and overall change in
relative amplitude to ﬂickering light
(r = )0.60, p < 0.001; Fig. 4B).
Fig. 2. Type 2 diabetes reduces retinal vascular vasoconstrictor responses to hyperoxia. Type 2
diabetic (Type2DM) subjects had attenuated retinal artery and vein vasoconstrictor responses
to hyperoxia compared with controls (group effect, p < 0.001).
Table 2. Resting haemodynamics.
Subjects Healthy controls 95% CI Type 2 Diabetes 95% CI p-value
HR (bpm) 60 ± 5 56, 63 68 ± 10* 63, 73 0.02
MAP (mmHg) 93 ± 8 88, 98 96 ± 15 92, 100 0.36
SBP (mmHg) 120 ± 9 114, 126 129 ± 15 122, 136 0.10
DBP (mmHg) 80 ± 7 75, 85 80 ± 7 77, 83 0.99
HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic
blood pressure; means ± SD; CI, conﬁdence intervals.
* Signiﬁcant difference between groups.
Table 1. Subject demographics, anthropometrics and fasting plasma blood biomarkers.
Healthy
controls 95% CI
Type 2
Diabetes 95% CI p-value
Number of subjects 10 20
Number of women ⁄men 5 ⁄ 5 7 ⁄ 13
Age (years) 50 ± 7 45, 55 56 ± 9 52, 60 0.06
Weight (lbs.) 205 ± 41 176, 235 194 ± 46 169, 212 0.50
BMI (kg ⁄m2) 30.7 ± 5.1 27, 34 30.4 ± 5.5 27, 33 0.89
Fasting glucose (mg ⁄ dl) 86 ± 7 80, 91 115 ± 30* 100, 129 0.01
Fasting insulin (mg ⁄ dl) 5 ± 3 16 ± 29 0.22
HbA1C (%) 5.2 ± 0.3 5.0, 5.4 7.2 ± 1.3* 6.6, 7.8 0.00
Duration diabetic (years) 7.2 ± 1.2
Total Cholesterol (mg ⁄ dL) 198 ± 33 175, 222 176 ± 35 159, 192 0.10
Low-Density Lipoprotein (mg ⁄ dl) 131 ± 29 110, 152 100 ± 32* 87, 114 0.01
High-Density Lipoprotein (mg ⁄ dl) 47 ± 12 38, 56 49 ± 12 43, 55 0.70
Lipid Ratio 4.2 ± 1.5 3.0, 5.3 3.8 ± 1.0 3.4, 4.2 0.30
Triglycerides (mg ⁄ dl) 92 ± 31 71, 114 130 ± 60 102, 158 0.07
BMI, body mass index; HbA1C, haemoglobinA1C; CI, conﬁdence intervals; means ± SD.
* Signiﬁcant difference between groups.
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These correlations were maintained
when glucose and insulin levels were
controlled for as covariates. A trend
for a relationship between constrictor
and dilator responses was observed
for the retinal veins (peak dilator:
r = )0.35, p = 0.06; and relative
amplitude: r = )0.32, p = 0.08)
(Fig. 4C,D); however, these vein cor-
relations were not signiﬁcant when
glucose and insulin levels were con-
trolled for as covariates. Lastly, we
found no relationship between hyper-
oxia-induced vasoconstriction and the
maximal vasoconstriction after peak
ﬂicker vasodilation.
Discussion
In this study, we examined (i) retinal
dilation responses to ﬂickering light,
(ii) vasoconstrictor responses to hy-
peroxia, (iii) the magnitude of change
to the stimuli, and (iv) the relationship
between retinal dilator and constrictor
responses to two stimuli in a group of
healthy controls and type 2 diabetic
subjects. We found attenuated vasodi-
lator and vasoconstrictor responses in
diabetic subjects to ﬂickering light and
hyperoxia and an inverse correlation
between ﬂickering light-induced vaso-
dilation and hyperoxia-induced vaso-
constriction. We propose that these
data suggest that (i) dilation during
ﬂicker and constriction during hyper-
oxia may share common vasoregulato-
ry factor(s) that are enhanced or
reduced and that (ii) these common
vasoregulatory factor(s) are abnormal
in diabetes. As abnormal nitric oxide
metabolism has been suggested to play
a role in the progression of diabetic
retinopathy (Maejima et al. 2001; Oz-
den et al. 2003; Izumi et al. 2006;
Toda & Nakanishi-Toda 2007; Ghosh
et al. 2011), we speculate that nitric
oxide may be the common vasoregula-
tor factor, which is known to be
altered in diabetic subjects, and medi-
ates both stimulus pathways.
Our hyperoxia data conﬁrmed
results from previous studies in which
diabetic subjects were noted to have
attenuated artery and vein vasocon-
strictor responses (Gilmore et al.
2007; Justesen et al. 2010). Previous
studies reported greater reductions
()10% to )14%) in retinal artery
and vein responses than those we
noted (5.6–5.8%) in our healthy older
individuals. Prior studies were gener-
ally performed in younger subjects
(Riva et al. 1983; Formaz et al. 1997;
Kiss et al. 2002; Jean-Louis et al.
2005), and the different oxygen
administration techniques used may
have led to decreases in CO2, which
may have enhanced the vasoconstric-
tor response in some of the earlier
studies. However, the magnitude of
change in artery vasoreactivity follow-
ing hyperoxia in our study’s control
group was similar to the magnitude
of change ()8%) previously reported
in middle-aged healthy subjects
(Justesen et al. 2010). We also
observed a similar magnitude in reti-
nal artery and vein responses to hy-
(A)
(B)
(C)
Fig. 3. A, B and C. Type 2 diabetes impairs retinal arterial dilation to ﬂicker stimuli. Type 2
diabetic (Type2DM) subjects had attenuated retinal artery and vein vasodilation responses to
ﬂickering light-induced stimuli compared with controls (group effect, p < 0.001; Fig. 2A). Reti-
nal vein vessels dilated to a greater degree than retinal artery vessels (vessel effect, p = 0.022).
There was no signiﬁcant difference in maximal vasoconstriction after peak vasodilation in either
vessel between groups or vessels (Fig. 2B); however, the percent change in relative amplitude in
dilation showed attenuated responses in diabetic subjects compared with controls (group effect,
p < 0.001; Fig. 2C). (% = percent).
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peroxia in the groups. Although the
speciﬁc mechanisms for this are
unclear, retinal arterial narrowing
and changes in arterial compliance
may contribute to small vessel stiff-
ness (Cheung et al. 2007) and thus
lead to attenuated arterial responses
to hyperoxia in diabetic individuals.
Our ﬂicker data conﬁrmed previous
studies examining retinal vessel
responses to ﬂicker in which normal
subjects demonstrate robust diameter
and blood ﬂow responses (Formaz
et al. 1997; Michelson et al. 2002;
Dorner et al. 2003; Nagel et al. 2004).
In contrast, disease states such as
diabetes demonstrate attenuated
dilator responses (Garhofer et al.
2004; Mandecka et al. 2007; Nguyen
et al. 2009; Pemp et al. 2009). As
noted earlier, the attenuated ﬂicker
response in diabetic retinal vessels has
been suggested to be partly due to
reduced nitric oxide (Schmetterer
et al. 1997).
Recent retinal autoregulation stud-
ies (Bek et al. 2008; Skov Jensen et al.
2011) have demonstrated an interac-
tion between two stimuli (ﬂickering
light and isometric handgrip) in
healthy and diabetic subjects, suggest-
ing the importance of examining
responses to several stimuli to further
understand mechanisms of retinal vas-
cular dysfunction. Thus, our study
examined whether a relationship exists
between hyperoxia and ﬂickering light
in further understanding vascular
function in healthy and diabetic sub-
jects. We observed similar changes in
magnitude of the retinal artery and
vein responses in both the control and
diabetic groups. In our study, the
magnitude of the hyperoxia-induced
vasoconstriction ()5.6% to )5.8%)
was similar to the magnitude in vaso-
dilation (5.3–6.9%) following light
ﬂicker stimulation of the arteries and
veins in the healthy control group.
This ﬁnding is in contrast to a previ-
ous study of healthy young subjects
(n = 3), which demonstrated a greater
magnitude change in hyperoxia com-
pared to ﬂicker (Formaz et al. 1997).
Reasons for these differences may be
due to technical differences (adminis-
tration set-up for hyperoxia, use of
fundus photographs, and duration of
ﬂickering light stimulus) and differ-
ences in the group’s ages. In our
(A) (B)
(C) (D)
Fig. 4. A, B, C and D. Correlation analysis between responses to hyperoxia and ﬂicker stimulation. (A). Retinal artery diameter responses to hy-
peroxia vasoconstriction (horizontal line) and ﬂickering light-induced vasodilation (vertical line) were signiﬁcantly correlated by Pearson’s method
(r = )0.56, p = 0.003). (B). Similar diameter associations were observed between hyperoxia vasoconstriction (horizontal line) and ﬂicker light
change in relative amplitude (vertical line) (r = )0.60, p < 0.001). (C). Retinal vein diameter responses to hyperoxia vasoconstriction (horizontal
line) and ﬂickering-induced vasodilation (vertical line) were not signiﬁcantly correlated by Pearson’s method (r = )0.35, p = 0.06). (D). Similar
diameter associations were observed between hyperoxia vasoconstriction (horizontal line) and ﬂicker light change in relative amplitude (vertical
line) (r = )0.32, p = 0.08). (White circles = Type 2 diabetic subjects; Black squares = control subjects).
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study, diabetic’s retinal diameter
responses were also similarly attenu-
ated in their magnitude response to
hyperoxia and ﬂicker. These autoregu-
latory vasodilator and vasoconstrictor
impairments in individuals with diabe-
tes may increase their predisposition
to microvascular complications such
as diabetic retinopathy (Kohner et al.
1995).
In our study, a common vasoregula-
tory factor(s) may help to explain the
30% of the variance between the two
stimuli in the retinal arterial responses
independent of glucose and insulin lev-
els. We speculated that this common
factor(s) includes nitric oxide. Animal
and human retinal studies suggest that
part of the ﬂickering light-induced
vasodilation can be explained by an
increase in the production of nitric
oxide (Buerk et al. 1996; Kondo et al.
1997; Dorner et al. 2003), whereas ani-
mal and human peripheral and coro-
nary studies suggest that part of the
blood vessel vasoconstriction associ-
ated with hyperoxia can be explained
through the increase in reactive oxygen
species, which can reduce nitric oxide
availability (Rubanyi & Vanhoutte
1986; Mak et al. 2002; McNulty et al.
2007). Yet, it must be noted that hy-
peroxia and ﬂicker may involve differ-
ent pathways and multiple intracellular
mechanisms that may be altered in dia-
betes (Kim J 2006). Animal and human
studies suggest that besides nitric
oxide, superoxide generation (Rubanyi
& Vanhoutte 1986; Zhilyaev et al.
2003; McNulty et al. 2007), endo-
thelin-1 (Takagi et al. 1996; Higgins
et al. 1998; Zhu et al. 1998; Dallinger
et al. 2000; Kawamura et al. 2002),
thromboxane A (Takagi et al. 1996;
Zhu et al. 1998), 20HETE (Takagi
et al. 1996; Zhu et al. 1998), cyto-
chrome-P450 (Takagi et al. 1996; Zhu
et al. 1998) and prostanoids (Yu et al.
2001) may be contributors to hyperox-
ia constrictor responses. Although ani-
mal and human studies suggest that
part of the ﬂickering light-induced
vasodilation responses can be
explained by an increase in the produc-
tion of nitric oxide (Buerk et al. 1996;
Kondo et al. 1997; Dorner et al. 2003),
other mechanisms such as an increase
in potassium may also play a role in
the response to ﬂicker stimulus (Buerk
et al. 1995).
In our study, the majority of the
diabetic subjects were using statin
therapy. Human and animal studies
suggest the use of statins may be asso-
ciated with improvements in macro-
vascular (Bellia A 2010) and
microvascular (Nagaoka et al. 2007)
function possibly through an antioxi-
dant or anti-inﬂammatory mechanism.
In our study, despite the use of statins
in the diabetic subjects, their retinal
reactivity to hyperoxia and ﬂickering
light was still greatly impaired com-
pared with that in healthy controls.
Further studies are needed to fully
explore the effect of statins on retinal
reactivity in diabetes.
Viewing the fundus of the eye
allows direct simultaneous measure-
ments of arterial and venous
responses. Early studies showed that
both retinal veins and arteries could
respond to vasodilator and vasocon-
strictor stimuli. Studies have typically
reported responses in both vessels but
have not compared the magnitude of
change between vessels. In our study,
the magnitude of change in retinal
artery and vein diameter responses
were similar during hyperoxia. Dur-
ing ﬂickering light stimulation, the
magnitude of peak dilation was
greater in the retinal veins compared
with that in the retinal arteries,
whereas the magnitude of maximal
vasoconstriction after peak vasodila-
tion trended to be greater in the reti-
nal arteries compared with that in
the retinal veins. It is difﬁcult to
compare the magnitude of these
responses with prior studies using
these stimuli owing to differences in
duration of the stimuli given and fre-
quency of the light stimulus used. In
our study, the retinal vessels chosen
were within 1–2 discs diameters from
the optic disc. Typically, compared
with retinal veins, retinal arteries in
this area have a thicker muscle layer
and may exhibit a greater vasocon-
strictor response effect to pressure
stimuli (Anad-Apte & Hollyﬁeld
2011). As endothelial cells line both
retinal arteries and veins (Anad-Apte
& Hollyﬁeld 2011), greater vein vaso-
dilator effects are unclear compared
with artery. Thus, comparison of reti-
nal arteries and veins to various stim-
uli and metabolites merits further
investigation.
Limitations: First, we lacked mea-
surement of arterial blood gases dur-
ing hyperoxia. Second, the slight
nonsigniﬁcant reduction in ETCO2
with hyperoxia could have contributed
to the vasoconstrictor effect seen;
however, this was only seen in our
diabetic subjects who had an attenu-
ated vasoconstrictor response. Third,
to obtain sufﬁciently dilated pupils,
we had to use phenylephrine in some
of our subjects, but the ﬁndings were
consistent when these individuals were
excluded from the analysis. Thus, we
do not feel that this affected our
results. Fourth, the order of our trials
had the potential of inﬂuencing our
results; however, we feel that this is
unlikely due to short duration of hy-
peroxia (5 min), a standard minimum
of time between trials (15 min), and
that there was no signiﬁcant difference
between resting retinal diameters prior
to any stimuli. Lastly, we were only
able to measure diameters, not blood
ﬂow, so it is possible that velocity
may be altered differently by the two
stimuli; however, we could not mea-
sure retinal blood velocity.
In summary, the attenuated
magnitudes of ﬂicker light-induced
vasodilation and hyperoxia-induced
vasoconstriction on the same visit in
individuals with type 2 diabetes are
comparable. Similar common
vasoregulatory factor(s) may help to
explain over 30% of the variance
between the two stimuli in the retinal
arteries. One suggested common vas-
oregulator factor is nitric oxide; how-
ever, other factor(s) may be involved
which contribute to this association.
Further studies are needed to deter-
mine which factors alter endothelial
function in diabetes which may allow
the development of new interventions
to prevent early stages of atheroscle-
rosis and retinopathy associated with
diabetes. Finally, the measured vascu-
lar responses may reﬂect direct
changes in physiology of blood vessels
and ⁄or the retinal neuroglial struc-
tures.
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